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Introduction {#sec001}
============

*Plasmodium vivax* is the predominant cause of malaria in many areas of the world, including South and Central America, where it represents 75% of malaria cases \[[@pntd.0008466.ref001]\]. *P*. *vivax* malaria was traditionally considered a low-risk uncomplicated infection, but in the past years an increasing number of reports have documented severe complications and death caused by this infection \[[@pntd.0008466.ref002]--[@pntd.0008466.ref004]\]. Complications of *P*. *vivax* infections include different manifestations, but severe anemia is among the most frequent, especially in children \[[@pntd.0008466.ref005], [@pntd.0008466.ref006]\]. Despite its growing prevalence, the mechanisms leading to complications during *P*. *vivax* infections are poorly understood.

Anemia in malaria is a multifactorial syndrome characterized by decreased erythropoiesis and by the loss of infected and uninfected erythrocytes \[[@pntd.0008466.ref007], [@pntd.0008466.ref008]\], which results in the loss of about 34 uninfected erythrocytes for each erythrocyte lysed directly due to *P*. *vivax* infection \[[@pntd.0008466.ref009]\]. The mechanisms underlying the loss of uninfected erythrocytes are not clear yet, but malaria-induced anemia was recently related to autoimmune responses in patients \[[@pntd.0008466.ref010]\]. Malaria, as other highly inflammatory infectious diseases, induces a strong autoimmune response characterized by the generation of anti-self antibodies with different specificities \[[@pntd.0008466.ref011]--[@pntd.0008466.ref013]\]. Studies in mice models of malaria showed that antibodies recognizing the lipid phosphatidylserine (PS) exposed on the surface of uninfected erythrocytes promote their clearance contributing to anemia \[[@pntd.0008466.ref014]\].

In malaria patients, the levels of anti-PS antibodies correlate inversely with hemoglobin levels in different cohorts infected with *P*. *falciparum*, including children with severe infections in Uganda \[[@pntd.0008466.ref015]\], European travelers with post-malarial anemia \[[@pntd.0008466.ref014]\] or first-time malaria infections \[[@pntd.0008466.ref016]\] and uncomplicated *P*. *vivax* infections in Malaysia \[[@pntd.0008466.ref017]\]. The relationship between-anti-PS antibodies and other autoantibodies with anemia has not been explored longitudinally or during complicated *P*. *vivax* infections. We hypothesized that anti-PS and other autoantibodies would correlate with anemia development during *P*. *vivax* malaria, particularly in complicated infections.

Previous reports show increased levels of atypical memory B-cells (AtMBCs) in populations chronically exposed to *P*. *falciparum* \[[@pntd.0008466.ref017]--[@pntd.0008466.ref021]\] or *P*. *vivax* infections \[[@pntd.0008466.ref022]\]. In *P*. *falciparum* acute infections, a strong correlation was observed between the levels of AtMBCs, the levels of anti-PS antibodies and the levels of plasma hemoglobin \[[@pntd.0008466.ref016]\], suggesting that atMBCs may be the main B-cell type secreting anti-PS antibodies that contribute to human malarial anemia, as was previously observed in mice models of infection \[[@pntd.0008466.ref023]\]. However, the relationship between AtMBCs, autoimmunity and the role they might play during anemia and other complications has not been explored during *P*. *vivax* infections. We hypothesized that AtMBCs would be highly expanded during complicated *P*. *vivax* infections and could be a key mediator of anemia though the secretion of autoimmune antibodies.

Here we present the first study of the relations between autoimmune antibodies, hemoglobin levels and AtMBCs in two different cohorts of *P*. *vivax* malaria patients from Colombia: one longitudinal comparing uncomplicated *P*. *vivax* and *P*. *falciparum* patients over the period of one month and one cross-sectional comparing complicated and uncomplicated *P*. *vivax* malaria.

Our results from the first cohort show that the levels of autoimmune antibodies and AtMBCs are maintained at least during one month after infection and correlate with anemia in both *P*. *vivax* and *P*. *falciparum* patients. In the second cohort, we analyzed the relations of different clinical and immune parameters of patients with uncomplicated or complicated *P*. *vivax* infections. A correlation analysis revealed a relation between autoimmune antibodies and hemoglobin levels in patients with complicated *P*. *vivax* infections, which were also related to levels of AtMBCs.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

Both studies included in this manuscript were approved by the Committee on Human Ethics of the Health Sciences Department of the University of Cordoba, Monteria, Colombia in Acta \#004 on May 6, 2016. Written informed consent was received from participants prior to inclusion in the study.

Study design and sample collection {#sec004}
----------------------------------

Two different studies on patients with malaria are included in this work ([Table 1](#pntd.0008466.t001){ref-type="table"}). The patients from both cohorts were recruited at the Tierralta municipality (8°10′22″N 76°03′34″O) in Córdoba, Colombia. This municipality expands for a total of 5.025 Km^2^, has an average temperature of 27.3°C and an altitude of 51 m ([S1 Fig](#pntd.0008466.s001){ref-type="supplementary-material"}). The malaria incidence in Tierralta is characterized for having stable transmission and high risk across the year, with an annual parasitological index above 10 cases per 1,000 habitants. In 2019, 9,111 malaria cases were reported, with 0.3% of them categorized as complicated malaria. *P*. *vivax* is the dominant species being reported, with a ratio of 4:3 *P*. *vivax* to *P*. *falciparum* \[[@pntd.0008466.ref024]\]. Patients for the first cohort to follow autoimmune responses over time were recruited at Hospital San José of Tierralta, Córdoba, Colombia, during six months in 2017 ([Table 2](#pntd.0008466.t002){ref-type="table"}). Uninfected controls were recruited in the urban, malaria non-endemic area of Monteria \[[@pntd.0008466.ref024]\]. Patients for the second cohort to compare uncomplicated and complicated *P*. *vivax* infections were recruited at Hospital San Jerónimo of Monteria and Hospital San José of Tierralta, Córdoba, Colombia, between October 2017 and March 2019 ([Table 3](#pntd.0008466.t003){ref-type="table"}). For both studies inclusion criteria were diagnosis of *P*. *vivax* by blood smear, confirmed by nested PCR \[[@pntd.0008466.ref025]\]. The WHO criteria for diagnosis of anemia \[[@pntd.0008466.ref026]\] and for severe *P*. *vivax* were followed \[[@pntd.0008466.ref006]\]. The most frequent complications in this group were thrombocytopenia (platelets ≤ 50,000/μL) in 64% (32/50) of patients; high alanine aminotransferase levels (\> 40 U/L) in 48% (24/50) of patients and hypoglycemia (glucose ≤ 60 mg/dL) in 42% (21/50) of patients. Only one patient presented severe anemia (hemoglobin ≤ 8 g/dL) while most patients suffered from moderate to mild anemia ([Table 4](#pntd.0008466.t004){ref-type="table"}). In both cohorts, patients were treated according to the National Health Institute of Colombia guidelines: Chloroquine (10 mg/kg, followed by 7.5 mg/kg at 24 and 48 h) and Primaquine (0.25 mg/kg for 14 days) \[[@pntd.0008466.ref027]\]. For all groups, children younger than 2 years old, pregnant women, and patients with other non-malarial infections (and *P*. *falciparum* for the cohort 2), were excluded. The following infections were excluded: Dengue, brucellosis, leptospirosis, salmonellosis, rickettsial disease and mixed *Plasmodium* infection. Control subjects for the second cohort were recruited in the municipality of Tierralta among afebrile people with no malaria episodes in the past 6 months. All were confirmed to be PCR negative for *Plasmodium* infection. Peripheral blood (5 ml in EDTA) was collected from each subject at the time of diagnosis and additionally at after 7, 14, 21 and 28 days for cohort 1. Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Paque density gradient system (Sigma). For all patients and control subjects of cohort 2, analysis of biochemical and cellular parameters was performed and demographic and epidemiological data were collected.

10.1371/journal.pntd.0008466.t001

###### Description of cohorts 1 and 2.

![](pntd.0008466.t001){#pntd.0008466.t001g}

  ----------------------------------- --------------------------- -----------------
                                      **Cohort 1**                **Cohort 2**

  **Study type**                      Longitudinal                Cross-sectional

  ***Plasmodium* species**            *P*. *vivax* (n = 11)\      *P*. *vivax*
                                      *P*. *falciparum* (n = 9)   

  **Community controls (CC)**         8                           50

  **Uncomplicated malaria (UM)**      20                          56

  **Complicated malaria (CM)**        \-                          50

  **Follow up days post treatment**   0, 7, 14, 21, 28            \-
  ----------------------------------- --------------------------- -----------------

10.1371/journal.pntd.0008466.t002

###### Clinical information from community controls, *P*. *vivax* and *P*. *falciparum*-infected patients from cohort 1.

![](pntd.0008466.t002){#pntd.0008466.t002g}

                                                           CC (n = 8)          *P*. *vivax* (n = 11)   *P*. *falciparum* (n = 9)   [\*](#t002fn001){ref-type="table-fn"}*P value Pv vs Pf*   [\*](#t002fn001){ref-type="table-fn"}*P value* CC *vs Pv*   [\*](#t002fn001){ref-type="table-fn"}*P value* CC *vs Pf*
  -------------------------------------------------------- ------------------- ----------------------- --------------------------- --------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Age (years)                                              25.5 (21.5, 28.7)   21 (13.0, 23,0)         13 (10.0, 21.5)             \-\--                                                     \-\--                                                       \-\--
  Female sex (%)                                           6 (75)              4 (36.3)                5 (55.5)                    \-\--                                                     \-\--                                                       \-\--
  Hemoglobin (g/dl)[\*](#t002fn001){ref-type="table-fn"}   13.4(13.53,14)      11.8 (11.0, 12.1)       11.2 (10.5, 12.0)           0.5389                                                    \<0.0001                                                    0.0013
  Parasite density (p/ μl)                                 0 (0, 0)            5,903 (4,913; 8,752)    7,733 (3,988; 8,865)        0.8633                                                    \-\--                                                       \-\--

\*Hemoglobin levels at nadir in *P*. *falciparum* and *P*. *vivax* patients.

Data presented as median (IQR) unless otherwise indicated

Abbreviations: community controls (CC), *P*. *vivax (Pv*), *P*. *falciparum* (*Pf*),

10.1371/journal.pntd.0008466.t003

###### Clinical information from community controls, *P*. *vivax* uncomplicated and complicated patients from cohort 2.

![](pntd.0008466.t003){#pntd.0008466.t003g}

                            CC (n = 50)         UM *P*. *vivax* (n = 56)   CM *P*. *vivax* (n = 50)   \*P value UM vs CM
  ------------------------- ------------------- -------------------------- -------------------------- --------------------
  Age (years)               20.5 (13.0, 33.2)   17.5 (12.7, 33.7)          16.0 (11.0, 26.0)          \-\--
  Female sex (%)            24 (48.0)           22 (39.3)                  24 (48.0)                  \-\--
  Hemoglobin (g/dl)         12.6 (11.5, 13.7)   11.5 (10.3, 12.7)          11.2 (9.9, 12.5)           0.5643
  Parasite density (p/μl)   0 (0, 0)            2,387 (1,800, 4050)        2,500 (1,460,5,185)        0.1421

Data presented as median (IQR) unless otherwise indicated

Abbreviations: community controls (CC); uncomplicated *P*. *vivax* malaria (UM); complicated *P*. *vivax* malaria (CM).

10.1371/journal.pntd.0008466.t004

###### Anemia status of patients from cohorts 1 and 2.

![](pntd.0008466.t004){#pntd.0008466.t004g}

  Grades of Anemia \[[@pntd.0008466.ref026]\]   Number of patients (%)                        
  --------------------------------------------- ------------------------ --------- ---------- ----------
  No anemia (\>11.9g)                           3 (27%)                  4 (44%)   21 (36%)   18 (36%)
  Mild (11.9g/dL---10.9g/dL)                    8 (73%)                  5 (55%)   21 (36%)   12 (24%)
  Moderate (10.8g/dL---8g/dL)                   0                        0         17 (28%)   19 (38%)
  Severe (\<8g/dL)                              0                        0         0          1 (2%)

Abbreviations: *P*. *vivax (Pv*), *P*. *falciparum* (*Pf*), uncomplicated *P*. *vivax* malaria (UM); complicated *P*. *vivax* malaria (CM).

Determination of antibodies {#sec005}
---------------------------

Costar 3750 96-well ELISA plates were coated with PS (Sigma) at 20 μg/ml in 200-proof Molecular Biology ethanol or a lysate of freeze-thaw control human red blood cells (RBC) (Interstate Blood bank) at (10^9^ RBCs/μl), calf thymus DNA (Sigma) at 10μg/ml and recombinant *P*. *vivax* MSP-1~19~ (BEI resources, MRA-60) in PBS. Plates were incubated during 16 h at 4 °C (ethanol evaporates completely). Plates were washed 3 times with PBS 0.05% Tween-20 and then blocked for 1 h at 37 °C with PBS 1X 3% BSA buffer. Plasma was diluted at 1:100 in blocking buffer and incubated for 2 h at 37 °C. Plates were washed again 3 times and incubated with a polyclonal sheep anti-human IgG-HRP diluted 1:2000 (GE Healthcare) in PBS 1X 0.5% BSA for 1 h at 37 °C. Plates were washed 3 more times and developed using TMB substrate (BD Biosciences). The reaction was stopped using Stop buffer (Biolegend) and absorbance read at 450nm. The mean OD at 450nm from replicate wells was compared with reference serum from a Colombian *P*. *vivax* patient previously identified as high responder for anti-PS IgG antibodies to calculate relative units (RU). A healthy USA control was used as a negative control to assess background, in addition to the uninfected endemic Colombian controls. ELISA methods were done as previously described\[[@pntd.0008466.ref015], [@pntd.0008466.ref016]\].

Flow cytometry {#sec006}
--------------

All flow cytometry was performed on a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ) and analyzed with FlowJo (Tree Star, Ashland, OR). All Abs for FACS were purchased from BioLegend (San Diego, CA). PBMC were stained with anti-human: FITC anti-CD20 (2H7), PE anti-T-bet (4B10), FITC anti-CD11c (3.9), FITC anti-CD27 (O323), FITC anti-CD21 (Bu32), APC anti-CD21 (Bu32), APC anti-FcRL5 (509f6), APC anti-CD10 (HI10a), and PRCP anti-CD19 (HIB19). Intracellular T-bet staining was performed using the True-Nuclear Transcription Factor Buffer Set (Biolegend) and following manufacturer's instructions. Two to three technical replicates (independent labeling of PBMC and FACS analysis) for B-cell subpopulations were performed when the number of PBMC collected from each patient allowed for it (80 samples for cohort 1 and 30 samples for cohort 2). The same 8 uninfected non-endemic Colombian controls from Monteria were used for both cohorts. The average value of technical replicates for each sample was used for statistical analysis.

Nadir calculation {#sec007}
-----------------

The lowest hemoglobin level reading during the longitudinal time series for each patient was chosen as the nadir. For all correlations of cohort 1, two anemic time points were used.

Statistical analysis {#sec008}
--------------------

Data were analyzed using Prism (GraphPad Software). Student t-tests or One-Way Anova were used to identify statistical differences between groups of samples. A p-value of \<0.05 was considered significant. Correlations were performed using non-parametric Spearman correlation analysis. Error bars represent the standard deviations (SD) of data from all of the patients used in each analysis.

Results {#sec009}
=======

Levels of autoantibodies between uncomplicated *P*. *falciparum and P*. *vivax*, infections {#sec010}
-------------------------------------------------------------------------------------------

In the first cohort, plasma samples from 20 patients with either *P*. *vivax* (n = 11) or *P*. *falciparum* (n = 9) uncomplicated infections were collected at the day of diagnosis (day 0), before patients received their first dose of treatment, and weekly during one month (days 7, 14, 21 and 28 (n = 99 unique samples). A large proportion of patients presented mild anemia (72.7% in *P*. *vivax* and 55.5% in *P*. *falciparum* patients) ([Table 4](#pntd.0008466.t004){ref-type="table"}). Both plasma and PBMC samples were also collected from uninfected healthy Colombians once (n = 8) ([Table 1](#pntd.0008466.t001){ref-type="table"}). First, we characterized the levels of relevant autoantibodies (PS, RBC and DNA) in *P*. *vivax* and *P*. *falciparum* patients across the different follow up samples at two time points where patients presented anemia. We observed a significant increase in the levels of all autoantibodies in both *P*. *falciparum* and *P*. *vivax* infections ([Fig 1A--1C](#pntd.0008466.g001){ref-type="fig"}).

![Levels of autoantibodies are increased in *P*. *falciparum* and *P*. *vivax* malaria patients.\
Bar graphs representing the levels of anti-PS (a), anti-RBC lysate (b) and anti-DNA (c) IgG antibodies at anemic time points between *P*. *vivax* and *P*. *falciparum* patients from cohort 1. Significance assessed by One-way Anova. \*p≤0.05, \*\*p≤0.01, \*\*\*\*p≤0.0001.](pntd.0008466.g001){#pntd.0008466.g001}

Longitudinal analysis of autoimmune antibodies, atypical memory B cells and hemoglobin levels in *P*. *vivax* patients {#sec011}
----------------------------------------------------------------------------------------------------------------------

We first analyzed the dynamics of autoantibodies and hemoglobin in the longitudinal samples from the first cohort, most of which suffered mild anemia ([Table 4](#pntd.0008466.t004){ref-type="table"}). The levels of hemoglobin varied over time for each patient, with most patients showing an initial decrease for 1--2 weeks until reaching the lowest hemoglobin concentration, or nadir, and a few showing a continuous increase in hemoglobin levels until recovery (n = 2 in *P*. *vivax* group) or an initial recovery followed by a later decrease (n = 2 in *P*. *falciparum* group). For this reason, the data were analyzed considering the nadir as the reference time, which is reached within one or two weeks difference between patients ([Fig 2](#pntd.0008466.g002){ref-type="fig"}). Importantly, there was no association between the levels of hemoglobin and parasitemia ([S2 Fig](#pntd.0008466.s002){ref-type="supplementary-material"}).

![Dynamics of autoantibodies and hemoglobin levels in Colombian *P*. *vivax* and *P*. *falciparum* patients.\
Longitudinal analysis of hemoglobin (black circles) and autoantibody (white circles) dynamics of Colombian *P*. *vivax* (a,c,e) and *P*. *falciparum* patients (b, d, f) normalized to the nadir in each patient. Significant assessed by paired Student T-test for differences for each point with the nadir value are indicated \*p≤0.05, \*\*\*p≤0.005).](pntd.0008466.g002){#pntd.0008466.g002}

Analysis of the levels of autoimmune antibodies in all *P*. *vivax* samples (n = 52 unique samples) revealed that anti-RBC, anti-PS and anti-DNA IgG antibodies follow an inverse pattern compared with hemoglobin levels, showing their highest levels close to the time of hemoglobin nadir ([Fig 2A, 2C and 2E](#pntd.0008466.g002){ref-type="fig"}). There was no significant difference between overall levels of autoantibodies between *P*. *vivax* and *P*. *falciparum* samples ([Fig 1](#pntd.0008466.g001){ref-type="fig"}). Anti-MSP1 antibodies also declined at the last follow up ([S3A Fig](#pntd.0008466.s003){ref-type="supplementary-material"}). The dynamics of all *P*. *falciparum* samples (n = 47 unique samples) followed similar trends where autoantibodies levels were inverse to hemoglobin and started declining after the nadir (day 7) which correlated with initial hematological recovery ([Fig 2B, 2D and 2F](#pntd.0008466.g002){ref-type="fig"}). This initial dynamic analysis suggests a relationship for these autoantibodies and anemia.

Correlation analysis of hemoglobin levels and different autoantibodies revealed an inverse relationship with anti-PS IgG antibodies ([Fig 3A and 3B](#pntd.0008466.g003){ref-type="fig"}) and other autoantibodies ([Fig 3C--3F](#pntd.0008466.g003){ref-type="fig"}) in both *P*. *vivax* and *P*. *falciparum*, suggesting a role in promoting anemia. As control, we observed that anti-*P*. *vivax* MSP1 IgG antibodies did not correlate with hemoglobin ([S3C and S3D Fig](#pntd.0008466.s003){ref-type="supplementary-material"}), highlighting the specificity of the correlation with autoimmune antibodies.

![Autoantibodies correlate with anemia in Colombian *P*. *vivax* and *P*. *falciparum* patients.\
Correlation analysis of hemoglobin levels and autoantibodies of Colombian *P*. *vivax* (a, c, e) and *P*. *falciparum* patients (b, d, f) at anemic points. Significance was assessed by non-parametric Spearman correlation analysis.](pntd.0008466.g003){#pntd.0008466.g003}

We then analyzed the different B-cell populations in this first cohort of patients in peripheral blood mononuclear cells (PBMC) samples obtained at the same times as the plasma (n = 48 for *P*. *vivax*, n = 32 for *P*. *falciparum* and n = 8 healthy controls). Following classical gating strategies for all relevant B-cell (CD19+) subpopulations from human PBMCs \[[@pntd.0008466.ref016]\], we analyzed: (i) naïve B-cells (CD27--CD21+ CD10--), (ii) immature B-cells (CD10+), (iii) plasma cells (CD27+CD21--CD20--), (iv) classical MBCs (CD27+CD21+) and (v) atypical MBCs (FcRL5+T-bet+).

We first analyzed the levels of AtMBCs in this Colombian cohort finding significant increases in *P*. *vivax* and *P*. *falciparum* patients compared to healthy controls. The total levels of AtMBCs were similar in *P*. *falciparum* and *P*. *vivax* patients ([Fig 4A](#pntd.0008466.g004){ref-type="fig"}). We then assessed the relationship between atMBCs with anemia, finding a significant negative correlation with hemoglobin levels in both *P*. *vivax* and *P*. *falciparum* patients ([Fig 4B and 4C](#pntd.0008466.g004){ref-type="fig"}). Immature B-cells were significantly expanded only in *P*. *falciparum* patients compared to controls ([Fig 4D](#pntd.0008466.g004){ref-type="fig"}), while plasma cells were the only B-cell population significantly more expanded in *P*. *falciparum* compared to *P*. *vivax* patients and controls. We also observed that other antibody-secreting B-cell populations did not correlate with anemia in *P*. *vivax* or *P*. *falciparum* patients, except for a significant inverse correlation between immature B-cells and hemoglobin only in *P*. *falciparum* patients ([S4 Fig](#pntd.0008466.s004){ref-type="supplementary-material"}).

![Atypical memory B-cell correlate with hemoglobin in Colombian *P*. *vivax* and *P*. *falciparum* patients.\
Graphs representing levels of atMBCs (a-c, e-j) or other B-cell populations (d) from PBMCs of Colombian uninfected controls, *P*. *vivax* and *P*. *falciparum* patients. Correlation analysis of atMBCs with either hemoglobin (b-c) or autoantibodies (e-j) of Colombian *P*. *vivax* (b, e, g, i) and *P*. *falciparum* patients (c, f, h, j) at anemic points. Significance assessed by One-way Anova (a,d) or by non-parametric Spearman correlation analysis (b-c, e-j). \*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.005. ^\#^significant between *P*. *vivax* and *P*. *falciparum*.](pntd.0008466.g004){#pntd.0008466.g004}

We then assessed the relationship between the levels of atMBCs with plasma autoantibody levels. Correlation analysis showed a positive relationship between the levels of atMBCs for most autoantibodies for both *P*. *vivax* ([Fig 4E, 4G and 4I](#pntd.0008466.g004){ref-type="fig"}) and *P*. *falciparum* ([Fig 4F, 4H and 4J](#pntd.0008466.g004){ref-type="fig"}). We found no significant correlation between previous malaria episodes and any of the autoantibodies tested or atMBCs ([S5 Fig](#pntd.0008466.s005){ref-type="supplementary-material"}).

Analysis of clinical parameters and autoimmune antibodies in patients with uncomplicated and complicated *P*. *vivax* infections {#sec012}
--------------------------------------------------------------------------------------------------------------------------------

In the second cohort, plasma samples from healthy community controls (n = 50), uncomplicated (n = 56) and complicated (n = 50) *P*. *vivax* infected patients were used for the determination of a battery of clinical and biochemical parameters. Among the criteria used for determination of complicated malaria, thrombocytopenia (platelets \< 50,000/μl) was the most frequent (66% of complicated patients). In this group, most patients suffered from mild to moderate anemia ([Table 4](#pntd.0008466.t004){ref-type="table"}) where the level of hemoglobin ranged from 6.8 to 15.1 g/dL. The average (11.2 g/dL) was lower than in uncomplicated (11.5 g/dL) or control (12.6 g/dL) groups, but still significantly higher than the established criteria for severe anemia (hemoglobin \< 8g/dL). As for the first cohort, plasma was also used to determine the levels of different autoimmune antibodies (anti-PS, anti-RBC and anti-DNA) and *P*. *vivax* anti-MSP1. For both uncomplicated and complicated *P*. *vivax* malaria patients, all autoantibodies were detected at higher levels than uninfected controls ([Fig 5A--5C](#pntd.0008466.g005){ref-type="fig"}). Anti-PS IgG antibodies were significantly increased in complicated compared to uncomplicated malaria patients. Antibodies against MSP1 were not different between the uncomplicated and complicated *P*. *vivax* malaria groups, but were higher than the uninfected control group ([S6 Fig](#pntd.0008466.s006){ref-type="supplementary-material"}).

![Correlation analysis of autoantibodies with epidemiological and clinical parameters in *P*. *vivax* patients with uncomplicated or complicated malaria.\
Bar graphs representing the levels of anti-PS (a), anti-RBC lysate (b) or anti-DNA (c) IgG antibodies in uninfected, uncomplicated or complicated *P*. *vivax* patients from cohort 2. A correlation matrix shows that anti-RBC, anti-PS and anti-DNA, but not anti-MSP1, correlate inversely with hemoglobin (Hg) in patients with complicated (CM) *P*. *vivax* (e), but not in uncomplicated (UM) (d). Spearman correlation coefficients are shown using the scale shown on the right, with positive correlations shown in red and negative correlations shown in blue. Boxes are marked with an "X" to show that the p-value for these pairwise correlations was \>0.05. Significance assessed by One-way Anova (a-c) or non-parametric Spearman Correlation (d-e). \*p≤0.05, \*\*p≤0.01, \*\*\*\*p≤0.0001.](pntd.0008466.g005){#pntd.0008466.g005}

Analysis of clinical parameters and autoantibodies identified different relations in the groups of uncomplicated and complicated *P*. *vivax* infections ([Fig 5D and 5E](#pntd.0008466.g005){ref-type="fig"}). In the group of complicated *P*. *vivax* infections, we observed a relation between the three autoimmune antibodies and erythrocyte count, hemoglobin, or hematocrit levels, suggesting that autoimmune antibodies may be related to the loss of erythrocytes in this population. No correlation was observed between anti-MSP1 antibodies and hemoglobin levels. These relations were not observed in patients with uncomplicated infections or healthy controls.

Autoimmune antibodies against PS and DNA correlate with hemoglobin levels in complicated *P*. *vivax* patients {#sec013}
--------------------------------------------------------------------------------------------------------------

Since autoimmune, and in particular anti-PS, antibodies have been proposed to contribute to malaria-induced anemia, we further analyzed the relation between autoimmune antibodies and hemoglobin levels in *P*. *vivax* malaria patients. Individual analysis revealed that in the group of uncomplicated patients, anti-RBC antibodies correlate inversely with hemoglobin levels ([Fig 6A](#pntd.0008466.g006){ref-type="fig"}), but no correlation was found for anti-PS ([Fig 6B](#pntd.0008466.g006){ref-type="fig"}), anti-DNA (*p* = 0.65) or anti-MSP1 (*p* = 0.09) antibodies. The level of parasitemia did not correlate with hemoglobin levels (*p* = 0.85), or with any of the antibodies.

![Autoantibodies correlate with anemia development in complicated *P*. *vivax* patients.\
Correlation analysis of hemoglobin levels and autoantibodies of Colombian *P*. *vivax* patients with uncomplicated (a-b) and complicated infections(c-f). Significance was assessed by non-parametric Spearman correlation analysis.](pntd.0008466.g006){#pntd.0008466.g006}

The autoimmune antibody response of patients with complicated *P*. *vivax* infections ([Fig 6C--6F](#pntd.0008466.g006){ref-type="fig"}) showed that all three autoimmune antibodies tested: anti-RBC, anti-PS and anti-DNA antibodies, correlate inversely with hemoglobin levels, establishing a relation between the malaria-induced autoimmune response and hemoglobin levels in this group. Antibodies recognizing the parasite antigen MSP-1 presented no correlation with hemoglobin levels.

No significant correlations were found between any of the antibodies determined and the levels of parasitemia in these patients (*p* values are 0.76 for anti-PS; 0.66 for anti-RBC; 0.83 for anti-DNA; 0.74 for anti-MSP1).

Atypical memory B-cells expand more and correlate with hemoglobin levels in complicated *P*. *vivax* patients {#sec014}
-------------------------------------------------------------------------------------------------------------

We then analyzed the relation of different B cell populations, including atMBCs and hemoglobin levels in *P*. *vivax* patients. First, we analyzed the levels of all relevant B-cell populations as described above ([Fig 4](#pntd.0008466.g004){ref-type="fig"}), in uninfected healthy controls (n = 8), uncomplicated (n = 12) and complicated (n = 18) *P*. *vivax* patients ([Fig 7](#pntd.0008466.g007){ref-type="fig"}). AtMBCs were significantly more expanded in complicated compared to uncomplicated *P*. *vivax* patients ([Fig 7A](#pntd.0008466.g007){ref-type="fig"}) and were the only B-cell population analyzed that was different between the *P*. *vivax* complicated and uncomplicated groups, suggesting that atMBCs may play a role in the severity of disease. Levels of immature B-cells were different when comparing uninfected controls and uncomplicated *P*. *vivax* patients ([Fig 7G](#pntd.0008466.g007){ref-type="fig"}). Naïve B-cells were significantly decreased only in the *P*. *vivax* complicated group, when compared to controls ([Fig 7I](#pntd.0008466.g007){ref-type="fig"}).

![atMBCs expand more robustly and correlate with hemoglobin in complicated *P*. *vivax* patients.\
Percentage within CD19+ gate (a, c, e, g, i) and correlation with hemoglobin (b, d, f, h, j) of atMBCs (a, b), classical memory B-cells (c, d), plasma cells (e, f), immature B-cells (g, h) and naïve B-cells (i, j) from PBMCs of uninfected controls and *P*. *vivax* patients with uncomplicated or complicated infections. Significance assessed by One-way Anova (a, c, e, g, i) or non-parametric Spearman correlation analysis (b, d, f, h, j). \*p≤0.05, \*\*p≤0.01.](pntd.0008466.g007){#pntd.0008466.g007}

We then analyzed whether any B-cell populations were related to hemoglobin levels in *P*. *vivax* infections. Analysis of all B-cell subtypes analyzed showed that only atMBCs presented a significant inverse correlation with hemoglobin ([Fig 7B](#pntd.0008466.g007){ref-type="fig"}), suggesting a role for these cells in malaria-induced anemia. There was a positive correlation between naïve B-cells and hemoglobin ([Fig 7J](#pntd.0008466.g007){ref-type="fig"}), which is in agreement with the levels of these cells being significantly lower in complicated *P*. *vivax* patients (which also present lower hemoglobin levels) compared to healthy controls ([Fig 7I](#pntd.0008466.g007){ref-type="fig"}). Other B cell populations did not show a relationship to hemoglobin levels ([Fig 7D, 7F and 7H](#pntd.0008466.g007){ref-type="fig"}), underscoring the specificity of the atMBCs.

Discussion {#sec015}
==========

Complications during malaria caused by *P*. *vivax* is an increasingly reported phenomenon for which we lack understanding of its etiology \[[@pntd.0008466.ref028], [@pntd.0008466.ref029]\]. Anemia is one of most reported complications associated with *P*. *vivax* malaria, but little is understood about the mechanism leading to it \[[@pntd.0008466.ref007], [@pntd.0008466.ref030], [@pntd.0008466.ref031]\]. In this study, we focused on characterizing the autoimmune B-cell response and its relation to malarial anemia in two different cohorts of malaria patients from Colombia, who suffered mostly from *P*. *vivax* malaria: one longitudinal in uncomplicated patients and one cross-sectional comparing uncomplicated and complicated patients. To our knowledge this is the first study to observe the presence and relationship of autoimmune antibodies, atMBCs and hemoglobin levels during *P*. *vivax* uncomplicated and complicated infections.

In the first cohort we observed a hemoglobin decrease in most patients for 1--2 weeks after treatment, which is consistent with previous studies in post-malarial anemia \[[@pntd.0008466.ref032]\]. We found that the levels of three different autoantibodies, anti-PS, anti-RBC and anti-DNA, correlated negatively with levels of hemoglobin in both Colombian *P*. *vivax* and *P*. *falciparum* malaria patients. Anti-PS antibodies may promote malarial anemia by targeting for clearance newly born uninfected erythrocytes, called reticulocytes, which prematurely expose PS during malaria infection \[[@pntd.0008466.ref010], [@pntd.0008466.ref014], [@pntd.0008466.ref033]\]. Since *P*. *vivax* preferentially infects reticulocytes\[[@pntd.0008466.ref034]\], anti-PS antibodies could also target infected reticulocytes exposing PS, however no correlation was found between parasitemia and levels of any of the autoantibodies, suggesting that the role of autoantibodies in controlling parasite growth is not decisive in *P*. *vivax* malaria.

Binding of anti-PS antibodies to uninfected erythrocytes probably explains, at least in part, the correlation we observed between anti-RBC and hemoglobin, since PS is highly abundant in erythrocyte lysates, along with other reported protein auto antigens (spectrin and band 3)\[[@pntd.0008466.ref012], [@pntd.0008466.ref035]\]. Antibodies against DNA also correlate with anemia in Ugandan children who suffered *P*. *falciparum* malaria \[[@pntd.0008466.ref015]\], but not in first-time infected European travelers \[[@pntd.0008466.ref016]\]. The mechanism by which anti-DNA antibodies are related to anemia is not established but could be mediated by the recently reported ability of erythrocytes to bind cell-free DNA on their surface \[[@pntd.0008466.ref010], [@pntd.0008466.ref036]\]. Similarly as for other *P*. *falciparum* cohorts \[[@pntd.0008466.ref015]\] \[[@pntd.0008466.ref016]\], no correlation was observed between anti-parasite antibodies (*P*. *vivax* MSP1) and hemoglobin. However, a correlation between hemoglobin levels and different *P*. *vivax* antigens, including MSP-1, has been described in other cohorts with larger numbers of patients \[[@pntd.0008466.ref037], [@pntd.0008466.ref038]\]. The number of patients in our first cohort is relatively small, due to the difficulties in obtaining weekly samples from already recovered patients that do not require further medical attention. Similarly, the sample size of complicated *P*. *vivax* cases is limited by the relatively infrequent appearance of these cases. Despite these limitations, our study indicates a significant correlation between hemoglobin levels and autoimmune antibodies. If a weaker relation between hemoglobin and anti-MSP-1 antibodies exists, possibly was not observed due to the smaller sample size.

AtMBCs are a highly reported B-cell subset known to expand in *P*. *falciparum*-exposed individuals in endemic areas \[[@pntd.0008466.ref018]--[@pntd.0008466.ref021], [@pntd.0008466.ref039]\] and in *P*. *vivax* patients \[[@pntd.0008466.ref022], [@pntd.0008466.ref040]--[@pntd.0008466.ref042]\]. Importantly, we have reported how *P*. *falciparum*-induced AtMBCs, characterized by double positivity of FcRL5 and T-bet, are able to secrete anti-PS antibodies *in vitro* and how they correlate with anemia in first-time infected *P*. *falciparum* patients \[[@pntd.0008466.ref016]\]. This led us to explore whether AtMBCs also correlated with anemia and autoantibodies in Colombian *P*. *vivax* and *P*. *falciparum* malaria patients. Our results show an equally strong negative relationship between atMBCs levels and hemoglobin in both *P*. *vivax* and *P*. *falciparum* malaria patients. Lastly, plasma autoantibodies significantly correlated with levels of atMBCs, suggesting their association with anemia might be due to their ability to secrete these autoantibodies. No other antibody-secreting B-cell sub-population correlated with anemia development in these patients suggesting specificity for these cells and a role in promoting this syndrome. Altogether these data suggest a new role for atMBCs during anemia during *P*. *vivax* infections possibly through autoantibody secretion.

A surprising finding from this cohort is the similar levels of autoantibodies and atMBCs in *P*. *vivax* and *P*. *falciparum* malaria patients, while the loss of uninfected erythrocytes is known to be higher in *P*. *vivax* infections \[[@pntd.0008466.ref009]\]. Our previous work in mice established a mechanism for the process of elimination of uninfected RBCs during malaria \[[@pntd.0008466.ref014]\]. The elimination of uninfected RBCs depends directly on two factors: the exposure of PS on the surface of the RBC and the binding of anti-PS antibodies to it. A similar mechanism probably occurs in malaria patients, but the relative levels of PS exposure in RBCs during *P*. *falciparum* and *P*. *vivax* infections is not known. We acknowledge that the small sample number for this cohort and limiting the analysis to the hemoglobin nadir time point could be additional factors influencing these results. Nevertheless, our results show that atMBCs and autoantibodies are expanded and correlate with hemoglobin levels in both *P*. *vivax* and *P*. *falciparum* malaria patients.

In our second cohort, we compared the same parameters (anemia, atMBCs and autoantibodies) between uncomplicated and complicated *P*. *vivax* infections. In both groups of patients, some expected relations between hemoglobin and different leukocyte populations, age and sex \[[@pntd.0008466.ref043], [@pntd.0008466.ref044]\], were observed. The analysis of this second cohort revealed a strong negative correlation between all autoantibodies and hemoglobin specifically in complicated *P*. *vivax* infections. In patients with uncomplicated *P*. *vivax* infections, we did not observe a correlation of autoantibodies with hemoglobin levels. This difference in the results with cohort 1, where all *P*. *vivax* patients were uncomplicated but their autoantibody levels correlated inversely with hemoglobin, is most likely due to the fact that longitudinal data in cohort 1 allowed us to identify the hemoglobin nadir, which was used for the correlation analysis. The samples in cohort 2 are from a single time point, which probably does not coincide with the nadir in most patients. These suggests a temporal aspect of the role of autoantibodies in malarial anemia during *P*. *vivax* infections.

atMBCs were the only B-cell sub population that was significantly higher in complicated compared to uncomplicated *P*. *vivax* malaria patients, and was also highly correlated with hemoglobin levels in this cohort. Accordingly, anti-PS IgG antibodies were also significantly higher in complicated compared to uncomplicated *P*. *vivax* malaria patients. Since atMBCs are able to secrete anti-PS antibodies \[[@pntd.0008466.ref016]\], their stronger expansion in complicated *P*. *vivax* infections could be directly linked to a pathological role. We observed a positive correlation between naïve B-cells and hemoglobin, which could be explained since both parameters had significantly decreased levels between complicated *P*. *vivax*-infected patients and uninfected individuals. Since naïve B-cells are not a source of antibodies \[[@pntd.0008466.ref045]\], they probably do not play a role in autoimmune anemia. Altogether, these results further support a role for atMBCs and autoantibodies in mediating anemia and identify these atMBCs as possible indicators of complicated infections in *P*. *vivax* patients.

In summary, our results show the first evidence of atMBCs are correlated with autoantibodies and anemia during *P*. *vivax* malaria, particularly during complicated infections. Given the need for a better understanding of complicated *P*. *vivax* infections, atMBCs constitute a novel component to the complex etiology of this syndrome.

Supporting information {#sec016}
======================

###### Geographical location of sampling point at the Tierralta municipality in Cordoba department of Colombia.

(TIF)

###### 

Click here for additional data file.

###### (Related to Figs [2](#pntd.0008466.g002){ref-type="fig"} and [3](#pntd.0008466.g003){ref-type="fig"}). Parasitemia does not correlate with hemoglobin in *P*. *vivax* and *P*. *falciparum* Colombian patients.

Correlation analysis of initial parasitemia (day 0) with hemoglobin of Colombian *P*. *vivax* (a) and *P*. *falciparum* (b) patients. Significance assessed by non-parametric Spearman correlation analysis.

(TIF)

###### 

Click here for additional data file.

###### (Related to Figs [2](#pntd.0008466.g002){ref-type="fig"} and [3](#pntd.0008466.g003){ref-type="fig"}). Dynamics of Anti-*P*. *vivax* MSP1 IgG antibodies in Colombian *P*. *vivax* patients.

(a-b) Longitudinal analysis of the dynamics of anti-*P*. *vivax* MSP1 IgG antibodies between day 0 and 28 post-treatment (a) and with hemoglobin (b). (c-d) Correlation analysis of anti-*P*. *vivax* MSP1 IgG antibodies for day 0 (c) and 28 (d) post-treatment with hemoglobin. Significance assessed by Unpaired Student T-test (a) and by non-parametric Spearman correlation analysis (c-d). \*p≤0.05.

(TIF)

###### 

Click here for additional data file.

###### (Related to [Fig 4](#pntd.0008466.g004){ref-type="fig"}). Levels of other B-cell populations in *P*. *vivax* and *P*. *falciparum* Colombian patients.

Correlation analysis of hemoglobin levels and classical memory B-cells (a-b), immature (c-d), naïve B-cells (e-f) and plasma cells (g-h) from PBMCs of *P*. *vivax* (a,c,e,g) and *P*. *falciparum* (b,d,f,h) patients at the two time points with lowest hemoglobin. Significance was assessed by non-parametric Spearman correlation analysis.

(TIF)

###### 

Click here for additional data file.

###### (Related to Figs [3](#pntd.0008466.g003){ref-type="fig"} and [4](#pntd.0008466.g004){ref-type="fig"}). Correlation of previous malaria episodes with autoantibodies and atypical memory B-cells.

Correlation analysis of previous malaria episodes with anti-PS (a, b), anti-RBC lysate (c, d) or anti-DNA (e, f) IgG antibodies or atMBCs (g, h) at anemic time points between *P*. *vivax* (a,c,e,g) and *P*. *falciparum* (b,d,f,h) patients from cohort 1. Significance was assessed by non-parametric Spearman correlation analysis.

(TIF)

###### 

Click here for additional data file.

###### (Related to [Fig 5](#pntd.0008466.g005){ref-type="fig"}). Anti-*P*. *vivax* MSP1 levels in uninfected and *P*. *vivax* patients with uncomplicated and complicated infections.

Bar graphs representing the levels of anti-*P*. *vivax* MSP1 antibody levels from plasma of uninfected controls and *P*. *vivax* patients with uncomplicated or complicated infection. Significance assessed by One-way Anova.

(TIF)

###### 

Click here for additional data file.
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Thank you very much for submitting your manuscript \"Atypical Memory B-cells and autoantibodies correlate with anemia during Plasmodium vivax complicated infections\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

All three reviewers have contributed tremendous feedback, with detailed analysis and valuable comments on how to improve the manuscript. As you address the comments, please pay particular attention to their suggested improvements, some which are numerous but hopefully not too onerous.
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When you are ready to resubmit, please upload the following:
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Sincerely,

Donelly Andrew van Schalkwyk, Ph.D.
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All three reviewers have contributed tremendous feedback, with detailed analysis and valuable comments on how to improve the manuscript. As you address the comments, please pay particular attention to their suggested improvements, some which are numerous but hopefully not too onerous.

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: (No Response)

Reviewer \#2: The manuscript by Rivera-Correa et al. points to an association of anti-PS autoantibodies and atypical memory B cells with anemia in two different cohorts of P. vivax patients, particularly in complicated P. vivax ones. They have now extended their previous work by showing a strong inverse correlation between different IgG autoantibodies (anti-PS, anti-DNA, and anti-RBC) and atypical memory B cells (atMBCs) with hemoglobin in both P. vivax and P. falciparum patients over time. Moreover, they reported a stronger association between hemoglobin levels, atMBCs, and anemia in complicated P. vivax patients compared to uncomplicated ones. Despite anemia is an important clinical manifestation of P. vivax infection, little is known regarding the mechanism underlying this disease outcome, thus the work is an important contribution to the field. However, there are several points that must be addressed to make it clearer and more robust.

\- The two main species that cause human malaria, P. falciparum and P. vivax, present biological particularities influencing the pathogenesis of severe infections, mainly anemia. The destruction of uninfected RBCs plays a crucial role in the etiology of vivax malaria, more than in P. falciparum infections. Thus, we expected an increase of anti-PS autoantibodies during vivax malaria when compared to levels in P. falciparum-infected patients. However, according to figure S2, the authors observed similar levels of autoantibodies (anti-Ps and anti-RBC) between P. vivax and P.falciparum Colombian patients. Do the authors have some explanation for such findings? Interestingly, levels of antibodies against RBC were lower than those verified for PS (please see fig. S2). In the same direction, levels of atMBCs were not different between patients infected with P. falciparum and P. vivax (Fig. S4). Those unexpected results in relation to the biological features of both parasite species were poorly discussed and deserve to be properly addressed. Moreover, I strongly recommend the authors to include figures S2 e S4 as part of the Results section, adjusting other figures to make the results more concise and direct (please see my comments below).

\- The pivotal novelty of the manuscript is the analysis of complicated malaria patients regarding their anemia status. However, it is not clear the criteria used to determine anemia and its classification according to the intensity as mild, moderate or severe. How many patients presenting complicated manifestation of vivax malaria had anemia (mild, moderate or severe)? Such information is essential to understand the relationship between anemia and autoantibodies and atMBCs.

\- The Introduction Section is too repetitive and, in my opinion, needs to be more focused, pointing the main concerns. I advise the authors to define the hypotheses to be tested in relation to the two cohorts evaluated in the study. This makes it very easy to understand the results and develop an appropriate discussion.

\- I strongly recommend authors to supply titles and statistical analyses for Tables. Currently, nothing is provided. Some are impossible to understand without such information.

\- The small sample size of patients enrolled in the Cohort 1 is worth addressing. This limitation of the research should be addressed in the Discussion aiming to explain the obtained results.

Reviewer \#3: The objectives of the study are well articulated however a hypothesis is not clearly stated. The study aims to test whether an association previously found in P. falciparum also exists in P. vivax, but using two different designs (longitudinal and cross-sectional) and additional types of patients. The population was clearly described and appropriate for the objetives.

The study was exploratory and the sample size was not large but it appeared sufficient to ensure adequate power to address some but not all objectives. A sample size or power calculation was not done for a primary analysis (which was not defined). Some correlations or dot plots had few points and that is probably the reason while statistical significance was not achieved in some of the secondary analyses.

The laboratory methods require more clarification: the ELISA for autoantibodies does not indicate the use of negative controls and the serum dilution is quite low (1/100), therefore there is concern about specificity of the response vs background response.

The statistical analysis used are quite simple but incompletely described. In methods it says that correlation analysis was Spearman but later they report Pearson in one occasion; Anova is not mentioned but later used, etc - revise consistency.

The study received ethical approval from the Colombian IRB where patients were recruited.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: (No Response)

Reviewer \#2: The authors need to remove any discussion, description of methods, references or conclusion from the results. They also need supply titles and, statistical analyses for Tables. Figures should be improved to highlight the main evidence. Please, consider joining some figure referring to related results.

Reviewer \#3: The analysis matches to a large extent the objectives presented (there was no proper analysis plan, just some simple methods listed).

Results are in general clearly and completely presented but since a lot of correlations are done, it needs to be better explained how they are interpreted. It appears the weight is given to the p values (highlighting in red) but it is better to give weight to the correlation coefficient (and state what intervals are considered relevant), and the scatter plots, rather than to the P value in such Spearman analyses but this is not well explained. In some cases a significant p value might not be convincing when looking at the r or scatter plots, while in others not significant p values can still appear significant looking at the correlation plot, only that too few samples were included. In general, however, the correlation coefficients are reasonable for the conclusions.

Some supplementary figures need to be polished in terms of format, e.g. spaces (between P. and falciparum or vivax), italics, etc. Tables ok.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: (No Response)

Reviewer \#2: Please, see the general comments above.

Reviewer \#3: In general, the conclusions are supported by the data presented.

The imitations of analysis are not clearly described and the discussion is rather short, this should be expanded. There is also no sufficienc discussion on the public health relevance of the findings or in how these data can be helpful to advance our understanding of the topic under study.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: (No Response)

Reviewer \#2: Minor comments:

\- Title: Include "anti-phosphatidylserine antibodies" since only those specific antibodies have been studied.

\- Line 29: 'are' do not fit in this sentence.

\- Line 35: add Colombia before South America.

\- Line 70: this sentence needs to be supported by a reference.

\- Line 72: the study conducted by Mourao et al. 2018 should also be cited here.

\- Line 104: The sentence "Very little is known about the pathogenesis of complicated P. vivax infections" must be removed.

-Line 109-111: Please, delete the affirmation since it was very premature and not directly related to the paper.

\- Line 123: Figure 1 is necessary? In my opinion, it could be changed to Fig. S2 and S6, showing the levels of antibodies against PS, RBC, and DNA in each cohort. As I mentioned above, those are unexpected results that deserve attention and discussion.

\- Line 126: Plasmodium vivax is a species, not a strain. Please, correct it.

\- Line 133: In my opinion, it would be more informative if the authors mentioned here criteria used to determine anemia and its classification according to the intensity as mild, moderate or severe. Besides this, it is also important to explain how the authors determined parasitemia.

\- Lines 127-132: Is there any overlap among patients from the two different cohorts?

-Table 1 is not adequate and must be improved to provide more information about cohorts and patients. How many patients were classified as presenting mild, moderate and severe anemia? According to the text, only one patient had levels of hemoglobulin above 7g/dL, what about the other two?

\- Line 137: "(hemoglobin ≤ 7gr/dL)" -- remove "r"

\- Line 141: Please, mention here what were the excluded infections.

\- Lines 141-143: Wouldn't it be better to use individuals who have never been exposed to malaria? Did the authors consider the last species infecting everyone? In an endemic area, how can you be sure that those individuals did not have any infection along the six months period? Did the authors also perform the diagnosis to discard a subpatent infection (as they could be asymptomatic individuals)?

\- Line 150: table 1 - Please, change "(11)" to (n = 11) and (n = 9)

\- Line 156: table 2 -- Did you evaluate the number of previous malaria episodes? In my opinion, this variable is important to understand different aspects of vivax malaria including the outcome of mild or severe disease. In this table, the authors should also include other information that was evaluated and is also important to characterize patients such as GPT, GOT, bilirubin direct, bilirubin total, creatinine, glycemia, platelets, leukocytes, erythrocytes, hematocrit, Hg. Do the authors have data about reticulocytes count? If yes, please include it.

\- Line 174: Which was the temperature used for blockage? Please, describe the blocking buffer.

\- Line 176: Please, mention the solution in which the secondary antibody was diluted.

\- Line 178-180: Please, indicate at least one reference supporting this method to determine autoantibody levels.

\- Line 198: For figure 2, the authors did not perform any statistical analysis. As they compared the measurements of Hb and antibodies for the same patients, before and after nadir, the statistical test must be paired. Please review the analysis and complete this information.

\- Line 201: replace "form" to "from"

\- Line 207-210: Please, clarify the number of studied individuals: "P. vivax (n =11) or P. falciparum (n = 9)" means 20 patients, not 17 as pointed. "(n = 99 unique samples)" -- is this the total number of samples collected in different moments? Please, confirm this.

\- Line 216: Since the authors are talking about proportion, it is better to mention the percentage in parenthesis rather than numbers (8/11 and 5/9).

\- Line 227: Change figure legend to Dynamics of autoantibodies and hemoglobulin levels in Colombian P. vivax and P. falciparum patients. Note that several patients are not anemic according to WHO criteria.

\- Lines 235-236: This statement seems to be not clearly depicted in the graphs. Please, adjust the information accordingly.

\- Line 243: In my opinion, the relationship between two variables is generally considered strong when their r value is larger than 0.7. This is not the case for values such as: 0.41, 0.48, 0.47, 0.50, 0.37. Therefore, the word strong should be removed.

\- Line 251: What does "the two time points with lowest hemoglobin" mean? Please, clarify.

\- Line 257: Correct to subpopulations.

\- Lines 271: Delete "in".

\- Line 301: What does it mean "possible relation"? There is a relation or not regarding the results presented.

\- Lines 312-313: Change figure legend to Correlation analysis of autoantibodies with epidemiological and clinical parameters in P. vivax patients with uncomplicated or complicated malaria.

\- Line 355-356: Why did the n change from this assay to the latter one?

\- Line 408-411: I missed some discussion about the relationship between reticulocytes and P. vivax. How can anti-PS autoantibodies influence on P. vivax infection, as this species exclusively invades reticulocytes?

\- Lines 416-417: There is some evidence in the literature showing increased anti-PvMSP1-19 levels, negatively correlated with a decrease in hemoglobulin levels see Sepulveda et al., 2016). Other P. vivax antigens have also been correlating to anemia as PvMSP3 (see Mourao et al., 2012). Consider discussing the results accordingly.

\- Line 420: remove South America since the main goal is not to evaluate geographical parameters but, outcomes related to P. vivax species that can be extrapolated to other patients living in vivax endemic areas.

\- Line 450: "...atMBCs constitute a novel component with diagnostic and

therapeutic potential for this syndrome." This statement should be moderated.

\- Figure 2: Add the word P. vivax above its corresponding graphs (a, c, e) and P. falciparum above b, d, and e. Moreover, correct the Y-axis of graph c (anti-RBC instead of anti-PS).

\- Figure 3: The same observation described in figure 2.

\- Figures 4 and 5 should be jointed as well as Figures 8 and 9.

Reviewer \#3: Editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity:

Abstract requires revising of the language (use of punctuation, selection of words, grammar, etc)

Atypical Memory B cells do not need capital letters at the early paragraphs.

In introduction reviese the use of words to avoid repetition of some terms.

Line 70: introduce a reference at the end of sentence.

There are key relevant papers missing on the presence of atypical memory B cells and P. vivax malaria that should be added, one in Latin America and the other in Papua New Guinea.

Review the use of abbreviations throughout to avoid duplicating definitions.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Anemia is a common symptom seen in both P. falciparum and P. vivax infections. It has long been known that the level of anemia is out of proportion to the number of erythrocytes that are lysed from parasite infection. Besides suppressed erythropoiesis there is a large component of lysis of uninfected erythrocytes which contributes to this anemia. This group, and others, have made significant recent strides in determining the cellular mechanisms behind this phenomenon in both mouse models and P. falciparum. This manuscript extends those findings to P. vivax, where lysis of uninfected vs infected erythrocytes might be even more skewed towards uninfected.

This paper reports on two cohorts of P. vivax patients -- one uncomplicated longitudinal cohort of both P. vivax and P. falciparum uncomplicated cases and one cross-sectional cohort comparing uncomplicated to complicated P. vivax infection. Although not overly innovative (the techniques are all identical to those used in previous studies in P. falciparum) the study is meaningful and impactful. The work had not previously been done in P. vivax and similarity to P. falciparum should not have been assumed.

The work is very nicely done. It is presented well and analysed appropriately. Several concerns are listed below:

Figure 2 -- the number of time points on the x-axis is confusing as presented. The Methods state that samples were taken and admission and then at d7,14,21, and 28 days after. That should result in a total of 5 times points. Why are there 7 time points on these graphs?

Figure 2 shows that P. vivax has more anti-DNA autoantibodies than P. falciparum. This was also shown in the Barber et al JID paper and deserves comment in the Discussion section.

Figure 3 -- the correlation of anti-DNA autoantibodies to anemia for P. falciparum is quite different from the results seen in the paper previously published by this group in eLife. Comments should be made.

Correlations between autoantibodies and anemia are seen in uncomplicated P. vivax in Cohort 1, yet they are NOT seen in the UCM cases in Cohort 2. Is that because of the natural history of P. vivax disease and the correlation would have developed later in the disease process? Or due to correlations only being seen in Cohort 1 when looking at the two lowest Hb points? This should be discussed. A reader that does not spend significant time in the manuscript might be confused with the apparent contradiction. The difference was also not mentioned in Lines 435 and 436.

The major contribution of this paper is extension of similar findings from P. falciparum to P. vivax. Given such, there should be at least a paragraph in the Discussion to compare and contrast the mechanisms in the two species. There might be hints of differences in anti-DNA autoantibodies. These should either be explained away or described in detail. There also are often numbers quoted that P. falciparum lyses 8 RBCs per every infected RBC, whereas P. vivax lyses 34:1. These numbers could either be explained as significantly different -- or described as likely to be 'statistically insignificantly different'.

Minor:

Line 136 -- hypoglycemia, not just 'glycemia'

Table 2 -- Consistency is needed with "." vs "," in numbers as well as the number of significant digits reported.

Line 207 -- does not add up

Line 296 66% vs 64% on line 135
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Reviewer \#2: Although the manuscript represents an important contribution to the field of knowledge, some flaws should be considered by the authors during resubmission: (i) absence of a clear criterion for the characterization of anemia (mild, moderate and severe) in the study population difficult the interpretation of the role of anti-PS autoantibodies and atMBCs during malarial anemia; (ii) absence of an adequate comparison and discussion of the immunopathological processes of anemia during P. falciparum or P. vivax malaria, also difficult the interpretation of the results.
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\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Erika Martins Braga

Reviewer \#3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>

10.1371/journal.pntd.0008466.r002

Author response to Decision Letter 0

4 Jun 2020

###### 

Submitted filename: Reviewer_responses_PNTDs_060220_final.pdf

###### 

Click here for additional data file.

10.1371/journal.pntd.0008466.r003

Decision Letter 1

Fuehrer

Hans-Peter

Deputy Editor

van Schalkwyk

Donelly Andrew

Guest Editor

© 2020 Fuehrer, van Schalkwyk

2020

Fuehrer, van Schalkwyk

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

9 Jun 2020

Dear Dr Rivera-Correa and Dr Rodriguez,

We are pleased to inform you that your manuscript \'Atypical memory B-cells and autoantibodies correlate with anemia during Plasmodium vivax complicated infections\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.
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The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.
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